Gender, ethnicity and genetics in cardiovascular disease: part 1: Basic principles

Area of Science:

• Pharmacology
• Genetics
• Clinical Trials

Background:

• Historically, drug trials predominantly featured white males, overlooking significant gender and racial variations in drug responses.
• Despite regulatory efforts since 1993, the inclusion of diverse populations in clinical trials remains limited.
• Documented gender and racial differences in pharmacodynamics and pharmacokinetics exist, impacting therapeutic outcomes.

Purpose of the Study:

• To review the fundamental scientific principles behind gender and ethnic differences in drug efficacy and safety.
• To highlight the importance of diverse representation in clinical pharmacology.
• To summarize pharmacodynamic and pharmacokinetic variations across genders and ethnicities.

Main Methods:

• Review of scientific literature on pharmacogenetics and pharmacodynamics.
• Analysis of genetic polymorphisms in cardiovascular genes and drug metabolism pathways.
• Synthesis of data on gender and ethnic variations in drug response.

Main Results:

• Genetic polymorphisms significantly influence drug metabolism and cardiovascular responses.
• Substantial pharmacodynamic and pharmacokinetic variations exist between genders and ethnic groups.
• These variations can lead to differential drug efficacy and safety profiles.

Conclusions:

• Addressing underrepresentation in clinical trials is crucial for personalized medicine.
• Understanding genetic and demographic variations is essential for optimizing drug therapy.
• Further research is needed to fully elucidate and mitigate disparities in drug response.